{"name":"Celularity","slug":"celularity","ticker":"CELU","exchange":"NASDAQ","domain":"celularity.com","description":"Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the Lifebank","hq":"Florham Park, NJ","founded":0,"employees":"~123","ceo":"Robert Hariri","sector":"Cell Therapy / Regenerative Medicine","stockPrice":0.81,"stockChange":0.02,"stockChangePercent":2.53,"marketCap":"$23M","metrics":{"revenue":54220000,"revenueGrowth":-77.4,"grossMargin":24.4,"rdSpend":17386000,"netIncome":-57892000,"cash":6175000,"dividendYield":0,"peRatio":-1.4,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"UCART19 patent cliff ($0.0B at risk)","drug":"UCART19","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Celularity Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Celularity reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $44.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Celularity Announces Collaboration with Merck to Develop Cancer Therapies","summary":"Celularity announced a collaboration with Merck to develop cancer therapies using its UCART platform.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPdTdWUXRCR3k0QUU3em1IOFlZMWhvODQ2ZDBtTnVNdkV2NjRFenZwWmJDanprUU5NcEZpSFk5R3ZjTHZDNzA2elZrT1VJU24tb0tHWWFsTnlwQ3pIemRhdWY3M1VCdzBlbldYSzZaZVREV0twREwzYnVCQndRZmNXUFFZLVBiWXVWSGVCZ0ZLNVBvQ1JPWWY0SFU1YXpzbFIwaHJ4eWFLUkROYllRTzJBNk9EZTU0blZUcmJMNUVn?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Barach Family Trust backs Celularity (CELU) with $10M notes and 9.56% stake - Stock Titan","headline":"Barach Family Trust backs Celularity (CELU) with $10M notes and 9.56% stake","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9iVUlBc25nSjVma0llczNLZTI1akJHMnhYN3VTdHRTT0M3bGZ4UVlXalJlaTJoUERIZFM2RmVxX21fbGlEdDVlSURHT3BiLUU1Tm9TVHZNQUxkQjNoXzdaOFB2NTZZaW1NUHNQVnB3?oc=5","date":"2026-03-21","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Celularity Inc (CELU) - Stock Titan","headline":"If You Invested $1,000 in Celularity Inc (CELU)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9jMWg3WEtuZENLaS0wdzctNy0wQzJBU0hoS0hiZU94eUktcnRFRmZDVF9QRGc1MUpMQ2tMaHFPNTJFM3VQSUtXbjEtdmgzeG5COTBNOTFxaExjREF2ZEHSAWNBVV95cUxPR1VNdTJiNTRma1NINGxsTm15Z1VTLWlpRTl4X2hrSFktTlFmZHVqWXJxQUpoQjBOMnp6eWx6Ui1CZ0ZnQ1hVRWl3M0pNVFpZTTFDdU96Z0pkTGlfN2pWQjc5bmM?oc=5","date":"2026-03-12","type":"deal","source":"Bitget","summary":"Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities -","headline":"Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPTEFtcVgtd0VGTnlTOFJuYkFETUJXWHV4ZG1ib3p2MEVEVDBiQk1RWHkxdGFwc2dxaDRWb0xjZ3JXSEgxN0ZyNkZ2RUdkaXY3Y25wQ0hqa2VCRDhqYUxYUmpHU0pHaFFNQld3OThyTlFuM0RuZDgtVU04YmduSnRBeTdrLVVWNXRWamwtV0JCX0hmbEZRYWMwMndqb1QtYVh4dnVHZEQ1OENzYVRZb3VMZnZwRUVrYmxLbkI0LWJB?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan","headline":"Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZUh2UEtRMzRFSUo1QnpDYnNIZlpMNWM1RFg5NXpWbU5VLVY3R1BoSTl0UmxtZzZWVlNDazNIcWlCSFpfb3hZckJvNU1jRU9YeF9NUWJCM2ZWQ19yUTNqSUFCRHpibm5RbWIwMV9sMEJ1WUpoM0JWSlZWNGlYSlJuT2EzaWpfa2h5dlZFMC13OHFLamFwV1pUMkZLUDFBYW9CYjV6emVhNmlkMWN6X2dob2Vua2lBQmZ3THhJ?oc=5","date":"2026-03-10","type":"deal","source":"Stock Titan","summary":"Celularity’s $35M license shifts focus to placental longevity therapies - Stock Titan","headline":"Celularity’s $35M license shifts focus to placental longevity therapies","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQdFpRSFdmSmpNZC1SV2hTTGJmZnV6c1EyVDJxdFdERnhtRGd2b1RmTnRnX1dqTVNtOXJ3Y0tseEpYQ0NaUzlVb2NWMjhUQ0c5Mml6QV9GYzZiSGtGbS16UmhBczRSTXc4aldmU0Y4emdFclFhRmdycy04SEt1VDQweXlMX19nX0RJRHUyRkZ0bHpJZnVQLW1OZHVLSkhNbm5XTmJYWkczakFtSkRpNHVkNk5GcXJzNzc3VXRzZncxMzBSVXVGNkZJ?oc=5","date":"2026-02-10","type":"pipeline","source":"ROI-NJ","summary":"Celularity of Florham Park gets $12.2M from sale of New Jersey net operating losses - ROI-NJ","headline":"Celularity of Florham Park gets $12.2M from sale of New Jersey net operating losses - ROI","sentiment":"neutral"},{"date":"2026-01-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPZ0hLRHFuaC1RX05LOWR5azdnRnFEQlhOcFR2aGdKNWUySnFNaVk0X1E3aUF0SFhrTVJjMUpZUDlOcW9tY3BvRXBBakRSbjd0TnVvbW9FWFFMS0FUNGNvUjlhcTh4RmNSU0ZRTVRlSy00NU1KTXFHQzRXcF92UEk2R2MxRzh4aVM3ekQyVnVnNA?oc=5","date":"2025-12-19","type":"pipeline","source":"Longevity.Technology","summary":"Celularity raises $12m to sharpen longevity strategy - Longevity.Technology","headline":"Celularity raises $12m to sharpen longevity strategy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-15","type":"regulatory","source":"simplywall.st","summary":"There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding - simplywall.st","headline":"There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNMVlRYUZVd0czLXlidGV3QkZxd3pYUE5udGkyTkZkUGE4R1pXMk5LeFUzUXpmSXhrYkNacGFfb2w5QURzS2VpVjE5SEE2NXIyb3Bjdy1ma08xcUwxa3I5V2pyWU5zUzNWRUZCN1RkZU5RNmdYNGxLT3pWdnQ4RUk4UmVEUDBNVXE2V3BjRjJzSQ?oc=5","date":"2025-08-18","type":"pipeline","source":"Yahoo Finance","summary":"Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt - Yahoo Finance","headline":"Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPQUJkNGlnVTBSRlFBWVpjN1dSUlJnOVZqdjVLMmRwRG9PdkQ4emlmYVN1SUhwZ1ZOWkhqNWw1V0hMd25Yb2dGRkRibjVUQXdnVUdUN2dacmxEZ0lPdFF4bUNURlFvM1h3ZUVibTVDNzBCeWU2NEJUZTlVenJPY05FSG5hRF9UbHZEbDlRdXp4TkxpeE5iTm1wLUF0NjlmTGJ0bW13NlU5ek16N25hNFV0dGhyb0JjQQ?oc=5","date":"2022-10-03","type":"pipeline","source":"citybiz","summary":"Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer - citybiz","headline":"Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE1XQ2JnNTNwYkpVa09CNmtUWHFveDNFSjVFZExiQXhaVFg4QWpSZ0tvalhCdzJXZlFyTzVlUzBFbmxKVFFvam9pQzNEODA3UHpIV0pGUnozLURqSEhKeUxpX0NQdTfSAWpBVV95cUxQelRLclNKMDB6eHpiNWpqRjZoNHN1NkVudlNLdlFTQjZma3RlOVpkQmJGdVNlOXR2VmFJLUlPVlFGUFlBNzJfcTZyMml1VUdQZE5EX2NrYjdPR0JVUnd3STZFVGZDOVk2aTh3?oc=5","date":"2021-02-15","type":"pipeline","source":"BioInformant","summary":"Dr. Robert Hariri – Placental Pioneer Launches Celularity with $250M Cash - BioInformant","headline":"Dr. Robert Hariri – Placental Pioneer Launches Celularity with $250M Cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9jRnYzRU9zMG0tNVRDME9zdWhNdml6dXFzNzNYd3hia1dGQ256VHNaWnloQzMzTWdZV1VMWmQyUXdrTnljZWw4bF9RMlo3SU90Ql82WUh0MURjNUFVYndJ0gFkQVVfeXFMTjRvZV9BRUN6UUV2ODJIaUFFLVdiN0VoRVoxMEduQXZXQjFqQnlYczhxNjB0QWV0bnU5X2FELVlrZkt3TUJucXM3aXZmUWhNNGUybEstd0RPWTRXOFVPNzBVOG0tVA?oc=5","date":"2020-11-18","type":"pipeline","source":"BioInformant","summary":"How Celularity is Leading the Next Evolution in Cellular Medicine - BioInformant","headline":"How Celularity is Leading the Next Evolution in Cellular Medicine","sentiment":"neutral"}],"patents":[{"drugName":"UCART19","drugSlug":"ucart19","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novartis","Gilead Sciences","Bristol Myers Squibb"],"therapeuticFocus":["Oncology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":54220000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":54220000,"period":"2024-12-31"},{"value":22771000,"period":"2023-12-31"},{"value":22771000,"period":"2023-12-31"},{"value":17975000,"period":"2022-12-31"},{"value":17975000,"period":"2022-12-31"}],"grossProfit":6476000,"grossProfitHistory":[{"period":"2025-12-31","value":6476000},{"period":"2024-12-31","value":39231000},{"period":"2023-12-31","value":6755000},{"period":"2022-12-31","value":-1690000}],"rdSpend":17386000,"rdSpendHistory":[{"period":"2025-12-31","value":15025000},{"period":"2024-12-31","value":17386000},{"period":"2023-12-31","value":30465000},{"period":"2022-12-31","value":78363000}],"sgaSpend":51266000,"operatingIncome":-61308000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-61308000},{"period":"2024-12-31","value":-38551000},{"period":"2023-12-31","value":-76479000},{"period":"2022-12-31","value":-148267000}],"netIncome":-57892000,"netIncomeHistory":[{"period":"2025-12-31","value":-91716000},{"period":"2024-12-31","value":-57892000},{"period":"2023-12-31","value":-196295000},{"period":"2022-12-31","value":14192000}],"eps":-2.64,"epsHistory":[{"period":"2024-12-31","value":-2.64},{"period":"2023-12-31","value":-11.02},{"period":"2022-12-31","value":0.95},{"period":"2021-12-31","value":-14.9}],"cash":6175000,"cashHistory":[{"period":"2025-12-31","value":6175000},{"period":"2024-12-31","value":738000},{"period":"2023-12-31","value":227000},{"period":"2022-12-31","value":13966000}],"totalAssets":132682000,"totalLiabilities":145391000,"totalDebt":40901000,"equity":-38062000,"operatingCashflow":-13254000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-13254000},{"period":"2024-12-31","value":-6401000},{"period":"2023-12-31","value":-38685000},{"period":"2022-12-31","value":-137876000}],"capex":-161000,"capexHistory":[{"period":"2024-12-31","value":-161000},{"period":"2023-12-31","value":-4048000},{"period":"2022-12-31","value":-5236000},{"period":"2021-12-31","value":-6203000}],"freeCashflow":-13254000,"dividendsPaid":-5900000,"buybacks":0,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":15064000,"ebit":-23462000,"ebitda":-21659000,"period":"2025-12-31","revenue":4104000,"epsBasic":null,"netIncome":-24362000,"rdExpense":3347000,"epsDiluted":null,"grossProfit":-3270000,"operatingIncome":-22058000},{"sga":9306000,"ebit":-21599000,"ebitda":-19775000,"period":"2025-09-30","revenue":5284000,"epsBasic":-0.88,"netIncome":-23076000,"rdExpense":4598000,"epsDiluted":-0.88,"grossProfit":1380000,"operatingIncome":-12900000},{"sga":12634000,"ebit":-22581000,"ebitda":-20747000,"period":"2025-06-30","revenue":5736000,"epsBasic":-1.02,"netIncome":-24524000,"rdExpense":3352000,"epsDiluted":-1.02,"grossProfit":494000,"operatingIncome":-15864000},{"sga":14262000,"ebit":-17317000,"ebitda":-15483000,"period":"2025-03-31","revenue":11426000,"epsBasic":-0.84,"netIncome":-19754000,"rdExpense":3728000,"epsDiluted":-0.84,"grossProfit":7872000,"operatingIncome":-10486000},{"sga":16058000,"ebit":-11481000,"ebitda":-9605000,"period":"2024-12-31","revenue":18132000,"epsBasic":null,"netIncome":-13293000,"rdExpense":3828000,"epsDiluted":null,"grossProfit":10789000,"operatingIncome":-9473000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.73,"netIncome":null,"rdExpense":null,"epsDiluted":-0.73,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.81,"previousClose":0.79,"fiftyTwoWeekHigh":4.35,"fiftyTwoWeekLow":0.71,"fiftyTwoWeekRange":"0.71 - 4.35","fiftyDayAverage":1.17,"twoHundredDayAverage":1.78,"beta":0,"enterpriseValue":91606896,"forwardPE":-1.4,"priceToBook":-1.14,"priceToSales":0.88,"enterpriseToRevenue":3.45,"enterpriseToEbitda":-1.7,"pegRatio":0,"ebitda":-54013000,"ebitdaMargin":-203.4,"freeCashflow":-5257375,"operatingCashflow":-13254000,"totalDebt":74713000,"debtToEquity":0,"currentRatio":0.15,"returnOnAssets":-30.9,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":36.4,"institutionHeldPercent":13,"sharesOutstanding":28945961,"floatShares":18817190,"sharesShort":275407,"shortRatio":7.99,"shortPercentOfFloat":0.9,"epsTrailing":-3.59,"epsForward":-0.57,"revenuePerShare":1.04,"bookValue":-0.71,"officers":[{"age":66,"name":"Dr. Robert Joseph Hariri M.D., Ph.D.","title":"Founder, CEO & Chairman"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.celularity.com","phone":"908 768 2170"}}